Akeso: all 165 studies

Page 2 of 2. Open to participants first (67), then studies with results posted, then the rest; newest registration first within each.

• A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell CarcinomaCompletedNCT05256472Phase 2
• A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With HyperlipidemiaCompletedNCT05255458Phase 3
• A Study to Evaluate the Efficacy and Safety of AK102 in Patients With HyperlipidemiaCompletedNCT05255094Phase 3
• AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLCActive, not recruitingNCT05247684Phase 2
• A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant TumorsCompletedNCT05235542Phase 1/2
• A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical CancerActive, not recruitingNCT05235516Phase 3
• A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant TumorsActive, not recruitingNCT05229497Phase 1/2
• A Study of AK117/AK112 in Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05227664Phase 2
• AK104 in Neoadjuvant Treatment of Cervical CancerCompletedNCT05227651Phase 2
• A Phase II Trial of AK104 in Advanced Non-Small Cell Lung CancerCompletedNCT05215067Phase 2
• A Study of AK112 in Advanced Malignant TumorsCompletedNCT05214482Phase 1/2
• A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114Status unknownNCT05200273Phase 1
• Phase 3 Clinical Study of AK112 for NSCLC PatientsActive, not recruitingNCT05184712Phase 3
• Study of AK119 in Subjects With Advanced Solid TumorsCompletedNCT05173792Phase 1
• A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe AsthmaTerminatedNCT05155020Phase 2
• A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With PsoriasisCompletedNCT05120297Phase 3
• Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLCCompletedNCT05116007Phase 1
• A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe PsoriasisCompletedNCT05096364Phase 2
• Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic DermatitisTerminatedNCT05048056Phase 2
• A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid TumoursCompletedNCT05021120Early Phase 1
• A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ AdenocarcinomaCompletedNCT05008783Phase 3
• A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian CancerTerminatedNCT04999605Phase 1/2
• A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical CancerActive, not recruitingNCT04982237Phase 3
• A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04980885Phase 1/2
• A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Phase 3
• A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLCCompletedNCT04900363Phase 1/2
• A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic SyndromeActive, not recruitingNCT04900350Phase 1/2
• Study of AK112 in the Treatment of Advanced Gynecological TumorsCompletedNCT04870177Phase 2
• A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical CancerCompletedNCT04868708Phase 2
• A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLCActive, not recruitingNCT04736823Phase 2
• A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal CarcinomaCompletedNCT04736810Phase 2
• A Phase 1 Dose Escalation and Expansion Study of AK117CompletedNCT04728334Phase 1
• A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedNCT04728321Phase 2
• A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT04647344Phase 1/2
• A Trial of AK104 Plus Anlotinib in NSCLCCompletedNCT04646330Phase 1/2
• A Study of AK112 for Advanced Solid TumorsCompletedNCT04597541Phase 1/2
• A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid TumorsCompletedNCT04572152Phase 1
• A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid TumorsCompletedNCT04547205Phase 1
• A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid TumorsTerminatedNCT04547101Phase 2
• A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy SubjectsCompletedNCT04516564Phase 1
• A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular CarcinomaCompletedNCT04444167Phase 1/2
• A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell LymphomaTerminatedNCT04444141Phase 1/2
• A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical CancerCompletedNCT04380805Phase 2
• A Study of PCSK9 Inhibitor AK102 in Patients With HypercholesterolemiaCompletedNCT04358432Phase 2
• A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104CompletedNCT04349969Phase 1
• A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic DermatitisCompletedNCT04256174Phase 1
• A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal CarcinomaCompletedNCT04220307Phase 2
• A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)CompletedNCT04173793Phase 2
• Clinical Study of AK101 in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT04173637Phase 2
• A Long-term Study of AK102 in Patients With HypercholesterolemiaCompletedNCT04173403Phase 2
• A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)CompletedNCT04172571Phase 2
• A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid TumorsCompletedNCT04172506Phase 1/2
• Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid TumorsCompletedNCT04172454Phase 1/2
• A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT04172233Phase 1/2
• A Study of PCSK9 Inhibitor AK102 in Healthy SubjectsCompletedNCT04169386Phase 1
• A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid TumorsCompletedNCT04047290Phase 1
• A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFHCompletedNCT03933293Phase 2
• A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung CancerCompletedNCT03866993Phase 3
• A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung CancerTerminatedNCT03866980Phase 3
• A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal CarcinomaCompletedNCT03866967Phase 2
• A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ AdenocarcinomaCompletedNCT03852251Phase 1/2
• A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin LymphomaCompletedNCT03722147Phase 1/2
• A Study of AK111 in Healthy SubjectsCompletedNCT03622021Phase 1
• Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid TumorsCompletedNCT03352531Phase 1
• Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid TumorsCompletedNCT03261011Phase 1

← Akeso overview and focus areas